Clinical Trials Logo

Keratoconjunctivitis clinical trials

View clinical trials related to Keratoconjunctivitis.

Filter by:

NCT ID: NCT00407043 Completed - Dry Eye Disease Clinical Trials

Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis

Start date: November 2006
Phase: Phase 4
Study type: Interventional

To evaluate the impact of Lotemax on the initiation of Restasis therapy in patients with dry eye. It is hypothesized that the anti-inflammatory activity of Lotemax may help mitigate the stinging with cyclosporine administration and the dry eye signs and symptoms experienced during the initiation of therapy.

NCT ID: NCT00357019 Completed - Clinical trials for Keratoconjunctivitis, Vernal

Study of the Clinical and Biological Efficacity of NAAXIA SINE® in Vernal Keratoconjunctivitis

Start date: April 2001
Phase: Phase 4
Study type: Interventional

To assess the clinical and biological efficacity of preservative free NAAGA eyes drops in vernal keratoconjunctivitis

NCT ID: NCT00349466 Completed - Clinical trials for Keratoconjunctivitis Sicca

Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca

Start date: January 2007
Phase: Phase 2
Study type: Interventional

This is a Phase 2, randomized, double-masked, placebo-controlled, parallel-group study in adult males and females, aged 18 years and over, with a diagnosis of moderate-to-severe keratoconjunctivitis sicca (KCS). Patients will be randomized to receive either CF101 1 mg or matching placebo, given orally every 12 hours (q12h) for 12 weeks. A Screening Period of up to 4 weeks that includes a 2-week run-in period will precede a 12-week treatment period, followed by a 2-week follow-up period.

NCT ID: NCT00345241 Completed - Clinical trials for Keratoconjunctivitis Sicca

Effects of Systane Versus Saline in Maintaining Tear Film Stability at Determined Time Points

Start date: January 2006
Phase: N/A
Study type: Interventional

To evaluate tear film stability of a market lubricant therapeutic eye drop versus saline when using Evaporometry and Interferometry in patients with a diagnosis of Keratoconjunctivitis Sicca (KCS). The purpose of this research is to evaluate evaporative parameters and tear film quality when using Systane lubricating eye drops versus saline in the eyes of dry eye patients at pre-instillation and at 30 and 60 minutes post instillation of drop(s).

NCT ID: NCT00328653 Completed - Clinical trials for Conjunctivitis, Vernal

Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC)

Start date: May 2006
Phase: Phase 2/Phase 3
Study type: Interventional

The primary objective of this study is: - To assess the efficacy of Nova22007, a cyclosporine A (CsA), 0.05% and 0.1% versus vehicle in patients with vernal keratoconjunctivitis (VKC) after a 4-week treatment period. The secondary objectives of this study are: - To compare the safety and ocular tolerance of Nova22007 0.05% and 0.1%; - To assess the long term safety and ocular tolerance of Nova22007 0.05% and 0.1%; and - To assess the decrease in frequency of concomitant artificial tears use.

NCT ID: NCT00201981 Completed - Clinical trials for Keratoconjunctivitis Sicca

Study of Rebamipide Eye Drops to Treat Dry Eye

Start date: May 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the potential safety and effectiveness of rebamipide eye drops, an investigational eye drop being developed for the treatment of keratoconjunctivitis sicca (dry eye).

NCT ID: NCT00201955 Completed - Clinical trials for Keratoconjunctivitis Sicca

Study of Rebamipide Eye Drops to Treat Dry Eye

Start date: May 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the potential safety and effectiveness of rebamipide eye drops, an investigational eye drop being developed for the treatment of keratoconjunctivitis sicca (dry eye).

NCT ID: NCT00167050 Recruiting - Clinical trials for Superior Limbic Keratoconjunctivitis

The Pathogenesis of Superior Limbic Keratoconjunctivitis

Start date: July 2005
Phase: N/A
Study type: Observational

Superior limbic keratoconjunctivitis (SLK) was first described in detail as a clinical entity by Frederick Theodore in 1963. The clinical picture of SLK is well documented, but the etiology is still unknown. This project will be conducted into through two parts: one is to investigate the presentation of chemokine receptors on mast cell and matrix metalloproteinases on fibroblasts by immunohistochemistry method from the pathological specimens of SLK patients who received conjunctiva resection as the treatment. The other part is to investigate the mRNA level of those chemokine receptors via reverse transcription - polymerase chain reaction from the conjunctiva collecting form SLK patients.

NCT ID: NCT00128245 Completed - Clinical trials for Keratoconjunctivitis Sicca

Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca

Start date: September 2004
Phase: Phase 2
Study type: Interventional

This study evaluates the efficacy and safety of 2 doses of pimecrolimus (0.3% and 1%) ophthalmic suspension in a moderate to severe population of keratoconjunctivitis sicca (KCS, dry eye syndrome) patients.

NCT ID: NCT00037661 Completed - Clinical trials for Keratoconjunctivitis Sicca

Study of INS365 Ophthalmic Solution in a Controlled Adverse Environment in Patients With Dry Eye

Start date: April 2002
Phase: Phase 3
Study type: Interventional

Comparative efficacy trial of INS365 Ophthalmic Solution and placebo in patients with dry eye.